Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Mr. Glenn P. Brame

Chief Technical Operations Officer

Ms. Betty Jean Swartz

Chief Business Officer

Mr. Eric J. Warren R.Ph.

Chief Commercial Officer

Dr. JoAnne Micale Foody FACC, M.D.

Chief Medical Officer

Mr. Sheldon L. Koenig

President, Chief Executive Officer & Director

Mr. Benjamin O. Looker

General Counsel

Mr. Benjamin  Halladay M.B.A.

Chief Financial Officer

Tiffany  Aldrich M.B.A.

Associate Director of Corporate Communications

Nombre	Capitalización
China Medical System Holdings Limited	0M
ZhuZhou QianJin Pharmaceutical Co.,Ltd	0M
Wockhardt Limited	0M
Chong Kun Dang Pharmaceutical Corp.	0.1M
Eris Lifesciences Limited	0M
Shenzhen Kangtai Biological Products Co., Ltd.	0M
Takeda Pharmaceutical Company Limited	0M
Medical Developments International Limited	0M
Alembic Pharmaceuticals Limited	0M
Hanmi Pharm. Co., Ltd.	0.3M
HANDOK Inc.	0M

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. Lista de competidores

Principales competidores